Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Silence Therapeutics, a UK-based biotechnology firm dedicated to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases, has extended the ongoing small interfering RNA (siRNA) delivery collaboration with AstraZeneca.
Subscribe to our email newsletter
As per the collaboration, which was signed on March 2008, the companies will leverage a number of Silence’s proprietary lipid delivery and targeting technologies to develop new delivery approaches for RNA interference (RNAi) therapeutics.
Under terms of the agreement, both companies retain the right to commercialise the novel delivery solutions that emerge from the collaboration. This agreement is independent of the companies’ other ongoing collaboration which is focused on developing novel RNAi therapeutics against specific disease targets exclusive to AstraZeneca.
Philip Haworth, CEO of Silence Therapeutics, said: “AstraZeneca’s desire to extend this collaboration offers important validation for the progress that our companies have already been able to make, as well as the fundamental siRNA delivery expertise that Silence possesses.
“The safe and effective delivery of RNAi therapeutics remains one of the key challenges in this emerging space and we are excited to be working hand in hand with a partner of AstraZeneca’s stature to achieve this goal.”